当前位置: 首页 >> 检索结果
3506. Serrated polyps <10 mm cannot reliably be characterized by i-Scan without magnification at routine colonoscopy.
作者: Sabrina Gg Testoni.;Chiara Notaristefano.;Giuliano F Bonura.;Maria Napolitano.;Dario Esposito.;Edi Viale.;Lorella Fanti.;Francesco Azzolini.;Giulia M Cavestro.;PierAlberto Testoni.
来源: Minerva Gastroenterol (Torino). 2024年70卷3期306-314页
Colorectal lesions (CRLs) <10 mm found at colonoscopy tend towards "diagnose-and-leave" or "resect-and-discard" strategies based on real-time Kudo glandular pit-pattern's assessment using i-Scan. However, i-Scan has not yet been validated for Kudo's classification. We aimed to assess whether, in routine colonoscopy, i-Scan without magnification and optical enhancement (M-OE) reliably differentiates hyperplastic polyps (HPs) from other serrated lesions (SLs) and conventional adenomas (CAs), and, among SLs, HPs from sessile serrated lesions (SSLs) and traditional or unknown serrated adenomas (TSAs, USAs), in Kudo type II CRLs<10 mm, according to ASGE Preservation and Incorporation of Valuable endoscopic Innovations (PIVI) recommended negative predictive value (NPV) threshold for adenomas.
3507. Lower end of treatment HBsAg and HBcrAg were associated with HBsAg loss after nucleos(t)ide analog cessation.
作者: Yandi Xie.;Minghui Li.;Xiaojuan Ou.;Sujun Zheng.;Yinjie Gao.;Xiaoyuan Xu.;Ying Yang.;Anlin Ma.;Jia Li.;Yuemin Nan.;Huanwei Zheng.;Juan Liu.;Lai Wei.;Bo Feng.
来源: BMC Gastroenterol. 2023年23卷1期224页
Since hepatitis B surface antigen (HBsAg) loss is rarely achieved with nucleos(t)ide analog (NA) treatment, most patients require life-long NA treatment. Previous studies have shown that some patients remain virologically responsive even after NA cessation. However, there is still controversy surrounding whether NA discontinuation increases the HBsAg loss rate. Therefore, this study aimed to assess the cumulative rate of HBsAg loss and identify the predictors of HBsAg loss after NA discontinuation.
3508. Efficacy of Crohn's disease exclusion diet in treatment -naïve children and children progressed on biological therapy: a retrospective chart review.
作者: María Clara Jijón Andrade.;Gemma Pujol Muncunill.;Ana Lozano Ruf.;Laura Álvarez Carnero.;Victor Vila Miravet.;Dolores García Arenas.;Natalia Egea Castillo.;Javier Martín de Carpi.
来源: BMC Gastroenterol. 2023年23卷1期225页
Recent trials suggested that the Crohn's disease (CD) exclusion diet (CDED) plus partial enteral nutrition (PEN) is a safe and effective strategy in remission induction of paediatric-onset CD. However, real-world evidence regarding the safety and efficacy of the CDED plus PEN approach is still lacking. The present case-series study reported our experience with the outcomes of CDED plus PEN in the paediatric-onset CD at disease onset and after the loss of response to biologics.
3509. An adjusted Asia-Pacific colorectal screening score system to predict advanced colorectal neoplasia in asymptomatic Chinese patients.
作者: Chenchen Zhang.;Liting Zhang.;Weihao Zhang.;Bingxin Guan.;Shuai Li.
来源: BMC Gastroenterol. 2023年23卷1期223页
The Asia-Pacific Colorectal Screening (APCS) score and its derivatives have been used to predict advanced colorectal neoplasia (ACN). However, it remains unknown whether they apply to the current Chinese population in general clinical practice. Therefore, we aimed to update the APCS score system by applying data from two independent asymptomatic populations to predict the risk of ACN in China.
3510. Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study.
作者: Yusuke Johira.;Takashi Nakahara.;Takahiro Kinami.;Shintaro Yamasaki.;Masanari Kosaka.;Yuki Shirane.;Ryoichi Miura.;Serami Murakami.;Shigeki Yano.;Kei Amioka.;Kensuke Naruto.;Yuwa Ando.;Yumi Kosaka.;Kenichiro Kodama.;Shinsuke Uchikawa.;Hatsue Fujino.;Atsushi Ono.;Eisuke Murakami.;Wataru Okamoto.;Masami Yamauchi.;Tomokazu Kawaoka.;C Nelson Hayes.;Masataka Tsuge.;Michio Imamura.;Hiroshi Aikata.;Shiro Oka.
来源: BMC Gastroenterol. 2023年23卷1期222页
Metabolic dysfunction-associated fatty liver disease (MAFLD) represents a new classification system for fatty liver disease. In this study, we investigated the clinical characteristics of patients with MAFLD-hepatocellular carcinoma (HCC) in comparison with those with nonalcoholic fatty liver disease (NAFLD) and considered the validity and challenges of the new criteria.
3511. Prevalence of Liver Steatosis and Fibrosis in the General Population and Various High-Risk Populations: A Nationwide Study With 5.7 Million Adults in China.
作者: Sailimai Man.;Yuhan Deng.;Yuan Ma.;Jingzhu Fu.;Heling Bao.;Canqing Yu.;Jun Lv.;Hui Liu.;Bo Wang.;Liming Li.
来源: Gastroenterology. 2023年165卷4期1025-1040页
This study aimed to estimate the prevalence of liver steatosis and fibrosis in the general population and populations with potential risk factors in China, so as to inform policies for the screening and management of fatty liver disease and liver fibrosis in general and high-risk populations.
3512. Identification and immunological characterization of cuproptosis-related molecular clusters in ulcerative colitis.
Ulcerative colitis is one of the two main forms of inflammatory bowel disease. Cuproptosis is reported to be a novel mode of cell death.
3513. Timing of endoscopy in patients with cirrhosis and acute variceal bleeding: a single-center retrospective study.
作者: Mengyuan Peng.;Zhaohui Bai.;Deli Zou.;Shixue Xu.;Chunmei Wang.;Metin Başaranoğlu.;Cyriac Abby Philips.;Xiaozhong Guo.;Xiaodong Shao.;Xingshun Qi.
来源: BMC Gastroenterol. 2023年23卷1期219页
The optimal timing of endoscopy in liver cirrhosis with acute variceal bleeding (AVB) remains controversial in current guidelines and studies.
3514. Laboratory risk factors for coexistent primary biliary cholangitis in patients with Sjögren's syndrome: a retrospective study.
作者: Xuan Gao.;Guangzhi Xiao.;Fengfan Yang.;Rongrong Dou.;Miao Xue.;Yingying Zhang.;Zhaohui Zheng.;Jin Ding.
来源: BMC Gastroenterol. 2023年23卷1期220页
Limited research exists on the laboratory characteristics of coexistent primary biliary cholangitis (PBC) and Sjögren's syndrome (SS). This study aimed to investigate the laboratory risk factors for the coexistence of PBC in patients with SS.
3517. Treatment and outcome of hepatorenal syndrome in Japan: a retrospective cohort study using a national inpatient database.
作者: Kazuya Okushin.;Hayato Yamana.;Ryosuke Tateishi.;Masaya Sato.;Takeya Tsutsumi.;Hiroki Matsui.;Kiyohide Fushimi.;Hideo Yasunaga.;Kazuhiko Koike.;Mitsuhiro Fujishiro.
来源: BMC Gastroenterol. 2023年23卷1期218页
Hepatorenal syndrome (HRS) is a life-threatening complication of end-stage liver disease. This study aimed to clarify the status of HRS in Japan by analyzing the Japanese Diagnosis Procedure Combination database.
3519. METTL3 regulates N6-methyladenosine modification of ANGPTL3 mRNA and potentiates malignant progression of stomach adenocarcinoma.
作者: Zhijin Zhang.;Jun Fu.;Yuhao Zhang.;Xianju Qin.;Yuexia Wang.;Chungen Xing.
来源: BMC Gastroenterol. 2023年23卷1期217页
N6-methyladenosine (m6A) is associated with mammalian mRNA biogenesis, decay, translation and metabolism, and also contributes greatly to gastrointestinal tumor formation and development. Therefore, the specific mechanisms and signaling pathways mediated by methyltransferase-like 3 (METTL3), which catalyzes the formation of m6A chemical labeling in stomach adenocarcinoma (STAD), are still worth exploring.
|